ABSTRACT Acetylcholine (ACh) and choline (Ch) levels in rat cerebrospinal fluid (CSF) were determined by in vivo microdialysis (CSF microdialysis) in both halothane-anesthetized and freely-moving rats. The Ch/ACh ratio in CSF perfused with Ringer's solution (30 ail/30 min) containing 10-5 M physostigmine, a centrally active cholinesterase inhibitor, was significantly lower than that in unprocessed CSF due to significantly higher ACh levels in the former. The successive measurement on the 2nd and 7th day after the guide cannula implantation demonstrated the feasibility of the CSF microdialysis method for repetitive monitoring of CSF ACh and Ch levels in freely moving rats without extensive tissue damage. Intra peritoneal administration of physostigmine caused an increase in CSF ACh levels, whereas administra tion of neostigmine, which cannot penetrate into the blood brain barrier, did not. Furthermore, a centrally active acetylcholinergic M,-receptor agonist, AF102B, produced an increase in CSF ACh and Ch levels. Thus, the present study demonstrates that CSF microdialysis is a useful method for evaluating overall cen tral cholinergic activity and investigating the pharmacological effects of various drugs that act via the central cholinergic system.
It has been reported that cerebrospinal fluid (CSF) measurements of constituents may provide information about brain biochemistry (1-3), since there are no major diffusional barriers between the brain extracellular fluid and the CSF (4) . The CSF neurotransmitter profiles at critical time points, therefore, should reflect neural activ ity because neurotransmitters and their metabolites are diffused rapidly via a bulk flow of the extracellular fluid from the sites of release into the ventricular space (5) . From a clinical point of view, an estimation of neuro chemical markers in CSF is important for diagnosis and assessment of a cure (3, (6) (7) (8) . Because of this, we have reported measurements of CSF neurotransmitters for evaluating the central neuronal activity in anesthetized rats (9, 10) .
Acetylcholine (ACh), one of the principle biogenic amines in the central nervous system (CNS), has been studied for its role in neuropsychological disorders, such as Alzheimer's disease (11, 12) and the dementia associated with this disease (13 16) , and its role in traumatic brain injury (17, 18) . Numerous reports also demonstrated that the aging process is associated with major changes in the central cholinergic functions including synthesis, storage and release mechanisms of ACh (19) (20) (21) (22) (23) . The CSF activ ity of the hydrolytic enzyme for ACh, acetylcholinesterase (AChE), is thought to be a reliable marker for evaluating the overall cholinergic activity of the CNS (3, 24) . CSF levels of the ACh have rarely been studied because of low concentrations due to the extremely rapid hydrolysis to choline (Ch). Recently, we have reported that central choli nergic function can be evaluated by measuring the CSF levels of ACh in anesthetized rats (9, 10, 25) .
Microdialysis is a well-established method for the in vivo measurement of neurotransmitters in the extracellu lar space (26) . Using this method, the extracellular ACh level has been determined in various brain regions includ ing the hippocampus, striatum and cerebral cortex. Sev eral studies indicate, however, that dynamic changes are induced by insertion of a dialysis probe into the brain (27) (28) (29) . Significant baseline differences in extracellular concentrations of neurotransmitters and their metabolites were noted following the time course of probe implanta tion. The CSF measurement of neurotransmitters permits the evaluation of the neuronal activity without extensive tissue damage (9, 10, 30) . Thus, in the present study, we applied in vivo microdialysis for measuring the CSF ACh level as a marker of central cholinergic activity in freely moving rats (CSF microdialysis). To assess the accuracy of this method, CSF ACh and Ch levels measured by microdialysis were compared with those measured by a direct method. An attempt was also made to elucidate the pharmacological effects of cholinergic drugs on the CSF ACh and Ch levels in order to evaluate the usefulness of CSF microdialysis as a pharmacological tool. 
MATERIALS AND METHODS

Procedures for in vivo microdialysis experiments
Under ketamine anesthesia, rats were chronically im planted with a polyethylene guide cannula with a guard formed by heating the cannula top and a polyethylene dummy cannula. As shown in Fig. 1 , the guide cannula was positioned in the cisterna magna and fixed on the atlanto-occipital membrane with the cannula guard. The correct locations of the guide cannulae were confirmed by overflow of CSF. One or two days after implantation of the guide cannula, rats were subjected to microdialysis for the determination of CSF ACh and Ch levels. After removal of the dummy cannula, an I-shaped dialysis probe (CMA/10; Carnegie Medicine, Stockholm, Sweden) was inserted into the cisterna magna through the guide cannula, and 1 mm of its membrane tip was kept free for exposure to CSF. The probe was connected to a microdialysis pump (CMA/100, Carnegie Medicine) and was continuously perfused at a flow rate of I pl/min with Ringer's solution containing a reversible AChE inhibitor, physotigmine (10 pM). After a 90-min equibration period, the perfused dialysate was collected at 30-min in tervals for 3 hr into an iced vial containing ethylhomo choline (EHC) as an internal standard. In some animals, experiments were performed again 7 days after the guide cannula implantation to assess whether dynamic changes in the output of ACh and Ch are observed after a longer post-implantation interval.
In another series of experiments, CSF ACh and Ch lev els in halothane-anesthetized rats were measured by direct assay and microdialysis methods. Anesthesia was induced with 3076 halothane and was then maintained with 0.8% halothane in 21016 02 and 79% N2 with a precalibrated halothane vaporizer (Fluotec 3; Cyprane Keighley, Eng land). CSF samples for direct assay were collected as previously reported (9, 10) . In brief, the atlanto-occipital membrane was exposured under a microscope and a poly ethylene guide cannula described above was inserted into the cisterna magna through it. Thirty minutes after intra cisternal cannulation, 30 to 50 ml of CSF was collected, from the natural cerebral flow, into an iced vial con taining 10 pmol physostigmine solution and EHC as an in ternal standard. For the microdialysis assay, the CSF was perfused with Ringer's solution containing 10-5 M physo stigmine, and a 30 min-sample was collected into an iced vial as described above. The dialysis efficiency of each probe was determined in vitro before dialysis. The probes were placed in the artificial CSF containing 1 uM ACh and Ch (pH 7.4, 371C) and were perfused with Ringer's solution at a flow rate of 1 i1/min. After equilibration, 30 ul samples (30-min samples) were collected in an iced vial through a polyethylene tubing. The dialysis efficiency (in vitro recovery) was calculated as the concentration in the dialysate/concentration in the surrounding artificial CSF x 100%.
Analysis of the CSF samples
ACh and Ch concentrations in the CSF samples, CSF dialysates or unprocessed CSF, were determined by a high performance liquid chromatography system with an electrochemical detector (HPLC-ECD: Acetylcholine Analytical System; Eicom Co., Ltd., Kyoto), as previous ly reported (9, 10) . Briefly, ACh and Ch were separated on an AC-Gel column (medium polarity stylenepolymer, 10 fim particle size, 150 x 6 mm) protected by a guard column (AC-ODS, 5 x 4 mm). An enzymatic post-column reactor containing immobilized AChE and choline oxi dase (AC-Enzympak, 5 x 4 mm) was used to convert ACh to hydrogen peroxide. The hydrogen peroxide was electro chemically detected by a platinum electrode set at + 450 mV vs. an Ag/AgCI reference electrode. The mobile phase contained 0.1 M sodium phosphate buffer (pH 8.5), 65 mg/I tetramethylammonium chloride and 300 mg/l so dium-l-decansulfonate.
The flow rate was maintained at 1.0 ml/min. The CSF samples were directly injected into the HPLC. The separation in the HPLC and the enzymat ic reactions were performed at 33C. ACh and Ch were identified by the retention time obtained from the stand ard compounds and were determined by the peak ratio to EHC. The detection limit of ACh assay was about 30 fmol/injection.
Animals and drug treatment
Male Wistar rats (300-350g weight, Scl: Wistar/ST; SLC, Hamamatsu) were used. Rats were housed in a group until surgery with free access to food and water. The light cycle was set at 07:00 19:00 hr and experiments were conducted between 10:00 and 19:00 hr. All handling of animals was performed in accordance with the Guide line for the Care and Use of Laboratory Animals by the Animal Research Committees of Hokkaido University School of Medicine.
EHC (N,N-dimethyl-N-ethyl-3-amino-l-propanol) was synthetized from N,N-dimethyl-3-amino-l-propanol and iodoethane by the previously described procedures (31) .
quinuclidine, was kindly donated by Snow Milk Brand Products Co., Ltd., Tokyo. All other chemicals used for HPLC analysis were of analytical grade and were ob tained from commercially available sources.
Data analyses
The data are expressed as means±S.E.M. Statistical differences between group means were determined by anal ysis of variance. The critical differences from the control mean were assessed with Dunnett's test. When appropri ate, comparisons between two group means were carried out using by the two-tailed Student's t-test. A level of P <0.05 was accepted as statistically significant. 
RESULTS
General observations
The presence of an AChE inhibitor, physostigmine, in the prefusion solution was required for the continuous quantificaion of CSF ACh. Moreover, perfusion of the rat CSF with a lower concentration of physostigmine (< 1 tM) often failed to demonstrate detectable ACh in the perfused dialysate (< 30 fmol/sample). All further ex periments, therefore, were carried out in the presence of 10 teM physostigmine in the perfusion medium.
In vitro recovery for each dialysis probe was deter mined before use. The average recovery for ACh and Ch was 16.8 ± 0.96% and 15.8 ± 1.0201o (n = 20), respectively. For comparison with the direct assay, ACh and Ch levels in the CSF dialysates, which were collected from the halothane-anesthetized rats, were calculated from the in vitro recovery of corresponding probes. As shown in Fig.  2 , CSF ACh levels obtained by microdialysis were sig nificantly higher than those obtained by direct assay of un processed CSF (P<0.01). However, a consistent differ ence was not observed between the CSF Ch values ob tained by microdialysis and direct assay. Thus, microdial ysis results showed a significant decrease in the Ch/ACh ratio (P<0.05).
In another series of experiments, time course changes of ACh and Ch in the CSF dialysates, which were collect ed during continuous perfusion, in freely moving rats were studied. As shown in Fig. 3 , relatively stable ACh levels were obtained from the onset of the perfusion throughout 4.5 hr in 5 out of 7 rats examined. ACh lev els of the remaining 2 rats reached equilibrium levels after 90 min of continuous perfusion. Dialyzed Ch was more stable than ACh. Based on these findings, 30-min samples collected 90 min after continuous perfusion were consi dered as the basal sample. The average basal values for the ACh, Ch and Ch/ACh ratio of conscious rats, calcu lated from the probe recovery, were 55.8 ± 8.6 pmol/ml, 6.7 ± 1.1 nmol/ml and 155.9 ± 29.9, respectively. In order to assess the repeatability of this technique, nine conscious rats were subjected to a successive sam pling of CSF dialyate on the 2nd and 7th day after the guide cannula implantation. ACh and Ch in the 30-min samples, which were collected 90 min after perfusion on each day, are presented in Fig. 4 . No significant difference was noted in the average concentrations of CSF ACh and Ch. ACh and Ch on the 2nd day were 57.4± 8.6 pmol/ml and 9.0± 1.2 nmol/ml; and on the 7th day, they were 58.5 ± 9.0 pmol/ml and 11.0 ± 2.0 nmol/ml, respectively.
The effects of intraperitoneally injected AChE inhibitors on CSF ACh and Ch levels
Physostigmine was intraperitoneally injected into the freely moving rat. CSF ACh and Ch levels for each rat were normalized to the basal (preinjection) value, which was defined as 100%. As shown in Fig. 5 , physostigmine (0.2 and 0.5 mg/kg) produced an increase in CSF ACh lev els in a dose-dependent manner. CSF ACh in the 30-60 min perfused dialysate in the 0.5 mg/kg-administered group was significanly higher than that in the saline-treat ed group (P<0.05).
The maximum response of ACh, which was defined as the mean of the highest values in the 30-min samples for each animal, was also increased sig nificantly by 0.5 mg/kg injection of physostigmine (P<0.05). CSF Ch did not exert any statistically sig nificant changes. Thus, the Ch/ACh ratio in the maxi mum response showed a dose-dependent decrease in the physostigmine-treated group; the response in the saline, 0.2 mg/kg and 0.5 mg/kg physostigmine-treated groups was 85.3±16.6% (n=9), 60.8±20.3% (n=8) and 50.6± 16.9% (n=7) of the basal ratio, respectively. Fig. 4 . Day-to-day changes of acetylcholine (ACh) and choline (Ch) levels in perfused cerebrospinal fluid samples in freely moving rats. Rats were subjected to microdialysis samplings on the 2nd and 7th day after the guide cannula implantation. See Fig. 3 for details. Fig. 5 . Effects of acetylcholinesterase inhibitors on cerebrospinal fluid levels of acetylcholine (ACh) determined by microdialysis in freely moving rats. Basal ACh and Ch levels calculated from the in vitro recovery of the corresponding dialysis probes were 53.26± 10.24 pmol/ml and 3.41 ± 1.22 nmol/ml (saline, n-9, open column); 69.18±25.61 pmol/ml and 4.22± 1.55 nmol/ml (physo stigmine 0.2 mg/kg, n=8, cross-hatched column); 72.85±26.57 pmol/ml and 6.82±1.71 nmol/ml (physostigmine 0.5 mg/kg, n=7, closed column); and 50.61±9.37 pmol/ml and 6.19±2.28 nmol/ml (neostigmine 0.5 mg/kg, n=6, shaded column), respectively. Values of 30-min samples for each individual rat were normalized to the basal value and were defined as 100%. "Maximum" indicates the highest values in 30-min samples for each animal after intra peritoneal administration of saline and acetylcholinesterase in hibitors. *P<0.05 vs. saline-treated controls.
Neostigmine (0.5 mg/kg, i.p.), a peripherally active AChE inhibitor, did not produce any significant changes in CSF ACh and Ch (Fig. 5) .
The effect of M, agonist on the CSF ACh and Ch levels AF102B, a centrally active M, agonist, was intra peritoneally injected into the freely moving rat. CSF ACh and Ch levels were individually normalized to the basal (preinjection) value as described above. AF102B (5 mg/kg) produced an increase in CSF ACh and Ch levels over a period of 120 min. The increase in CSF Ch levels in the 30 60 and 90 -120 min samples were statistically significant as compared with the saline-treated controls (P<0.05-0.01, Fig. 6 ). Maximum responses of ACh as well as Ch increased significantly by AF102B injection when compared with the saline-treated group (P<0.01); the responses of ACh and Ch in the 5 mg/kg AF102B treated group were 250.1-+30.407o and 270.3±37.107o (n = 7), respectively. Fig. 6 . Effects of AF102B on cerebrospinal fluid levels of acetylcholine (ACh) and choline (Ch) determined by microdialysis in freely moving rats. Basal ACh and Ch levels, which were calculated from the in vitro recovery of the corresponding dialysis probes, were 53.26± 10.24 pmol/ml and 3.41 ± 1.22 nmol/ml (saline, n=9, open column) and 60.41 ± 18.52 pmol/ml and 4.98 ± 1.02 nmol/ml (AF 102B 5 mg/kg, n = 7, cross-hatched column), respectively. Saline and AF102B were administered intraperitoneally. *P<0.05 and **P <0 .01 vs. saline-treated controls. See Fig. 5 for details.
DISCUSSION
In vivo microdialysis was applied to measure CSF ACh and Ch of both anesthetized and freely moving rats. For the accurate detection of ACh in the dialysate, the AChE inhibitor physostigmine (10 jM) was added to the perfu sion medium. In halothane-anesthetized rats, ACh levels of the CSF dialysates calculated from the in vivo recovery of the corresponding probes were higher, and the Ch/ACh ratios were lower than those determined by direct assay of unprocessed CSF. These differences are likely due to the inhibitory effect of physostigmine, in fused via the microdialysis probe, on conversion of ACh to Ch, since comparable Ch/ACh ratios in the CSF dialy sates were validated under two experimental conditions, in freely moving and anesthetized rats. In freely moving rats, CSF ACh and Ch levels were revealed to be relative ly stable over a period of 3 hr after the onset of con tinuous perfusion with a fixed concentration of physostig mine (10 tM). Moreover, our CSF microdialysis results indicate the feasibility of day-to-day repetitive measure ments of CSF ACh and Ch, because ACh and Ch levels on the 2nd and 7th day after the guide cannula implanta tion were almost identical. The CSF microdialysis tech nique was further validated by studying the effects of vari ous cholinergic drugs on CSF ACh and Ch levels in freely moving rats. Intraperitoneal injections of physostigmine caused a dose-dependent increase and decrease in CSF ACh levels and Ch/ACh ratios, respectively. On the other hand, another type of AChE inhibitor, neostigmine, which cannot penetrate into the blood brain barrier did not produce any significant changes in either CSF ACh levels or Ch/ACh ratios. These ACh and Ch profiles of CSF dialysates might reflect the pharmacological charac teristics of the anti-AChE agents used.
An extensive pharmacological evaluation of CSF microdialysis for ACh determination was also carried out on an acetylcholinergic M1-receptor agonist, AF102B. This drug is known to be highly selective for M1-type muscarinic receptors through binding studies using radio ligands in rat cerebral cortex and cerebellar homogenates (32, 33) . In the present study, intraperitoneal adminis tration of AF102B resulted in a significant increase in CSF ACh and Ch levels. AF102B, but not the M2-receptor agonist oxotremorine, has been reported to produce an increase of ACh release from the striatum and hippo campus in freely moving rats (34) . The increased-CSF ACh and Ch levels observed in our study might reflect that AF102B enhanced ACh output at M1 sites in the rat brain including the striatum and hippocampus.
Pharmacol ogical and behavioral studies have shown that AF102B ameliorated cognitive dysfunction in animal models of Alzheimer's disease (35, 36) , which are characterized by central cholinergic deficiency (37, 38) . We have reported that AF102B exerts an ameliorating effect on the impair ment of the passive avoidance response (39) in stroke prone spontaneously hypertensive rats, which showed a marked decrease in the CSF ACh level (25, 40) . We also observed that AF102B restored the ACh level in CSF dialysates of this vascular dementia animal model (H. Togashi, unpublished data). These findings suggest that the AF102B-induced ameliorating effect of memory impairment might be closely correlated with its pharma cological effects on the central cholinergic system. The pre cise mechanisms underlying AF 102B-induced increases in CSF ACh and Ch have not been solved. Mochida et al. (41) reported that AF102B generated slow depolarization in rabbit superior cervical ganglia. Thus, one possible explanation is that AF102B stimulates postsynaptic M1 receptors and produces slow depolarization in the rat brain as well. It is also likely that AF 102B acts on the presynaptic M2-receptor (autoreceptors) as a partial agonist and enhances the ACh release by inhibiting the negative feedback mechanism (34) . Moreover, AF102B may interact with other neuronal systems via heterorecep tors. As previously reported, muscarinic agonists potenti ate the evoked dopamine release from the cerebral cortex and striatum in a M1-receptor antagonist (pirenzepine) sensitive manner (33, 42) . Therefore, it is possible that AF102B act on central M1-receptors, which might be in volved in the direct and/or indirect ACh release in the cen tral nervous system, and result in an increase in the CSF ACh and Ch levels.
Little is known about the physiological and patho physiological significance of the CSF Ch levels. It has been suggested that the extracellular Ch might not be a good index for cholinergic activity, since Ch levels do not correlate to the changes in extracellular ACh levels (43) . However, we previously reported that the central cholinergic dysfunction observed in the vascular dementia animal models was accompanied with a decrease in CSF Ch as well as ACh (9, 10, 25, 40) . The present results also indicate that AF102B produced an increase in CSF Ch as well as ACh. On the other hand, physostigmine decreased the ratio of CSF Ch to CSF ACh dose-dependently, presumably resulting from AChE inhibition. These find ings might reflect the pharmacological effects of the cen trally active cholinergic drugs. Thus, Ch/ACh profiles in CSF are likely to provide more information for under standing the pharmacological characteristics of drugs act ing via the central cholinergic systems. In vivo brain microdialysis has been demonstrated to be a powerful tool for neurophysiological and pharma cological studies that require neurotransmitter levels in the extracellular space of animals to be continuously monitored (26) . However, several studies indicate that it is an invasive technique since dynamic changes are in duced by the insertion of a dialysis probe into the brain (27) (28) (29) . An acute activation of dopamine metabolism was observed in response to the implantation of the microdialysis probe to the rat striatum (27, 28) . It has also been demonstrated that neurotransmitter profiles in perfu sates are affected by the time course of various tissue reac tions around the probe membrane (27, 29) . In order to eliminate the tissue damage caused by the probe insertion, we have developed the CSF microdialysis technique for pharmacokinetic and behavioral studies (30) . The present study further demonstrates that microdialysis techniques are feasible for the repetitive and day-to-day determina tion of CSF ACh and Ch as an index of the central cholinergic activity in freely moving rats. Although one limitation of the CSF microdialysis technique is that the effective sites of action of systemically administered drugs cannot be determined, worthy of note is the fact that the pharmacological effect of a centrally acting M1 agonist, AF102B, on the hippocampus (34), in which cholinergic neurons have an important role, was also detectable in the present study using CSF microdialysis. The necessary addition of physostigmine to the perfusion solution is another limitation. However, it should be realized that the physostigmine concentration in the CSF surrounding the dialysis membrane will be one order of magnitude low er than that in the perfusion medium because of the limit ed efficiency of the dialysis probes. This might be support ed by the fact that the pharmacological effects of centrally and peripherally active AChE inhibitors could be evaluat ed under the present experimental conditions.
In conclusion, the CSF microdialysis was demonstrated to be a simple and non-invasive method for the measure ment of CSF ACh and Ch. This method has great poten tial for investigating the pharmacological effects of exog enous compounds on the central cholinergic system in awake, freely moving rats as well as in anesthetized rats. The approach to determine the absolute concentration of compounds in the extracellular fluid using appropriate in ternal standards (44, 45) will increase the value of the CSF microdialysis method. 
